Chronic obstructive pulmonary disease (COPD) is a chronic disease with high mortality and morbidity worldwide. Patients with end-stage COPD frequently develop chronic hypercapnic respiratory failure (CHRF) associated with end-of-life. In that stage of disease, treatment options are limited.

Long-term nocturnal noninvasive ventilation (NIV) has been applied in patients with chronic alveolar hypoventilation for decades. While there is no doubt that applying chronic nocturnal NIV improves outcomes in patients with restrictive and neuromuscular diseases,1 in COPD patients, only recently has evidence showing benefits of long-term NIV become available.2-4 However, despite these positive findings, the application of long-term NIV in patients with severe COPD should be carefully considered, as knowledge gaps exist with regard to patient selection, the optimal setting to initiate NIV, and the optimal ventilatory settings to be used.

In the October issue of the Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation, Weir and colleagues again show that high-intensity nocturnal NIV can indeed improve daytime gas exchange in COPD patients with CHRF.5 Interestingly, they aimed to use very high inspiratory pressures (as they describe: the inspiratory positive airway pressure [IPAP] was titrated from a minimum of 20 cm H2O up to the maximum IPAP tolerated with a maximum of 30 cm H2O; backup breathing frequencies [BF] set on the ventilator were gradually increased beyond the spontaneous BF to 18-22 breaths/minute). This resulted in a mean IPAP of 27.3 ±4.7 cm H2O and a mean backup BF of 15.4 ±2.9 breaths/min. Despite the fact that the authors spent a huge amount of effort to increase compliance with the ventilator after hospital discharge, with daily telephone calls the first 4 days, and weekly telephone calls thereafter, compliance was disappointingly low. Two patients dropped out and only 5 of 9 patients had an adherence of at least 4 hours use per night on 5 out of 7 nights per week. Furthermore, 4 of 9 patients had a COPD exacerbation during the follow up period. This disappointing compliance, relatively high drop-out rates and high exacerbation rates might explain why only limited-to-no additional improvements in health-related quality of life (HRQoL)
and lung function were found. Nevertheless, the paper does nicely address some important discussion points regarding long-term NIV in stable COPD.

First, we have learned that chronic NIV does not provide benefit in every COPD patient with CHRF. Unfortunately, we are insufficiently informed about the factors predicting a favourable response. Studies have shown us a few aspects that are important to recognize in selecting the appropriate patients. Patients with more severe CHRF seem to benefit more. Furthermore, benefit will only be achieved if patients truly suffer from prolonged CHRF. Chronic NIV will not improve outcomes once it is initiated in every patient who remains hypercapnic after an exacerbation as a large part of these patients will recover to normocapnia spontaneously and thus, do not need chronic NIV. Windisch et al published the results of a randomized cross-over trial, showing that high-intensity NIV was indeed more effective compared to low-intensity NIV, each applied for 6 weeks. However, the patient number was small (14 patients) and only medium-term effects (6 weeks) of each mode were tested. Consequent randomized controlled trials confirmed these results and have shown that with nocturnal NIV with settings aimed at really improving ventilation (reaching normocapnia at daytime), improvement in HRQoL, lung function, and even survival can be achieved.

Despite these promising findings of high-intensity NIV, important points remain to be discussed. First, survival benefit of high-intensity NIV as compared to standard care has been shown in only one, although large and well designed, randomized controlled trial. The survival benefit found in this study is, however, difficult to compare with the other long-term trials as the mortality was relatively high in the control group. Nevertheless, we believe it will, at least in our country (the Netherlands), raise ethical concerns to perform another large randomized controlled trial comparing NIV with standard care in patients with CHRF once such a large survival benefit has been shown in a group of patients for whom treatment options are limited. Secondly, although with high-intensity NIV, true benefits of chronic NIV in stable COPD were shown for the first time, we lack knowledge about what the optimal setting should be, what the true mechanisms leading to benefits of this mode of ventilation are and what disadvantages can be expected. Is it really the main aim to improve PaCO$_2$ or is the improvement in PaCO$_2$ an expression of another underlying mechanism being more important for improvement in HRQoL and survival? Should we focus only on this PaCO$_2$ or include other parameters too when initiating NIV? Currently, as we are incompletely informed about the mechanism of why long-term NIV improves long-term patient-related outcomes it is difficult to answer this question.

Some additional notes can be made regarding the ventilatory settings used. High-intensity NIV in patients with stable COPD was reported first by Windisch et al. They showed, in an uncontrolled study in 14 COPD patients with severe CHRF (mean baseline partial arterial carbon dioxide pressure [PaCO$_2$] 59.5 mmHg), that NIV with a high mean IPAP of 29.8 cm H$_2$O, combined with a high backup BF of 22.9 breaths/min, could reduce PaCO$_2$ from 59.5 to 46.0 mmHg during spontaneous breathing at daytime. These data were confirmed in their own cohort of patients ventilated with high-intensity NIV in a retrospective analysis published 3 years later. In this study it was shown that with a mean IPAP of 27.7 cm H$_2$O and a BF of 20.8 breaths/min a reduction in daytime PaCO$_2$ of 6.9 mm Hg and an improvement in lung function could be achieved after 2 months. However, these data were uncontrolled. In 2011, Dreher et al published the results of a randomized cross-over trial, showing that high-intensity NIV was indeed more effective compared to low-intensity NIV, each applied for 6 weeks. However, the patient number was small (14 patients) and only medium-term effects (6 weeks) of each mode were tested. Consequent randomized controlled trials confirmed these results and have shown that with nocturnal NIV with settings aimed at really improving ventilation (reaching normocapnia at daytime), improvement in HRQoL, lung function, and even survival can be achieved.
trial Murphy et al. showed that a setting with only high IPAP is as good as a setting with high IPAP and high backup BF. Furthermore, the number of hours use per day could be at least as important as the pressures and frequencies used. However, compliance might be a problem when (too) high-intensity settings are used. Finally, the drawbacks of high-intensity NIV are not completely clear yet. It was shown that high-intensity NIV might reduce cardiac output, and that it might increase patient-ventilator asynchrony. Unfortunately, data on these potential disadvantages are limited or not there at all.

The data of Weir et al., although uncontrolled, nicely draws our attention again to the potential benefits but also pitfalls and potential factors limiting benefits of high-intensity NIV. Future research will be needed to unravel these issues and optimize the treatment with long-term NIV of the increasing number of stable hypercapnic COPD patients with CHRF.
References


